Dharminder Chahal

Dharminder Chahal has built an extensive network in the life science industry and a strong track record in complex corporate transactions. These include the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, the sale of deVGen to Syngenta and the sale of Octoplus to Dr. Reddy’s. As a CEO, board member or advisor he is active for several European companies such as SkylineDx, CardioGenx, BioInvent, VitalneXt, BioGeneration Ventures II, Thuja Capital Fund, Gilde Healthcare Funds II and III and Innate Pharma.